Erbitux Misses Primary Endpoint As First-Line Treatment In Phase III NSCLC Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb/ImClone’s future for Erbitux in first-line NSCLC hinges on FLEX study findings, scheduled for release in first half of 2008.
You may also be interested in...
Erbitux Open-label Results For NSCLC Hardly Stellar
Still, the BMS-099 study supports results of the much larger and better-powered FLEX study, ImClone says.
Erbitux Open-label Results For NSCLC Hardly Stellar
Still, the BMS-099 study supports results of the much larger and better-powered FLEX study, ImClone says.
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC
Bristol-Myers Squibb/ImClone/MerckKGaA’s cetuximab significantly prolongs survival in the first-line treatment of NCSLC.